Pushing back against questions about the company’s recent earnings amidst a growing debate over drug-price reform in Washington state, a top executive for pharmaceutical company Johnson & Johnson called the company’s drug pricing “very responsible.”
One participant during a conference call in October asked Johnson & Johnson CFO Dominic Caruso if the pharmaceutical giant would pledge to not raise drug prices beyond the cost of inflation, but the executive did not seem willing to make that promise, according to The Intercept.
